Other
The Matthew Larson Foundation for Pediatric Brain Tumors
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
Failure Rate
50.0%
1 terminated/withdrawn out of 2 trials
Success Rate
50.0%
-36.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed trials have results
Key Signals
1 with results
Enrollment Performance
Analytics
Early Phase 1
1(50.0%)
Phase 1
1(50.0%)
2Total
Early Phase 1(1)
Phase 1(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT02962167Phase 1Completed
Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
Role: collaborator
NCT02212574Early Phase 1Terminated
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
Role: collaborator
All 2 trials loaded